Vanguard Portfolio Management
CRVS icon

Vanguard Portfolio Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Vanguard Portfolio Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.2M Buy
814,750
+144,855
+22% +$2.01M ﹤0.01% 2137
2026
Q1 		$9.8M Buy
+669,895
New +$10.7M ﹤0.01% 2119

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Portfolio Management's CRVS Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Corvus Pharmaceuticals (CRVS) stake by 22% in Q2 2026, buying an estimated $2.01M and bringing the position to 814,750 shares worth $12.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2137.

Vanguard Portfolio Management first reported a position in CRVS in Q1 2026 and has held it in 2 quarters since. 172 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Vanguard Portfolio Management held 814,750 shares of Corvus Pharmaceuticals worth $12.2M as of Q2 2026.
  • Vanguard Portfolio Management bought 144,855 Corvus Pharmaceuticals shares in Q2 2026, an estimated $2.01M.
  • Corvus Pharmaceuticals made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2137 holding.
  • Vanguard Portfolio Management first reported a position in Corvus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 172 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.